TRAIL-R2 (human):Fc (human) (rec.)
|Synonyms||DR5; TNFRSF 10B; CD262; Tumor Necrosis Factor Receptor Superfamily Member 10B; TRAIL Receptor 2|
|Source/Host||HEK 293 cells|
|Sequence||The extracellular domain of human TRAIL-R2 (aa 52-212) is fused to the Fc portion of human IgG1.|
|Specificity||Binds to human and mouse TRAIL.|
|Biological Activity||Blocks human or mouse TRAIL activity in a concentration of 1-10μg/ml.|
|Endotoxin Content||<0.01EU/μg purified protein (LAL test; Lonza).|
|Concentration||1mg/ml after reconstitution.|
|Reconstitution||Reconstitute with 50μl sterile water.|
|Formulation||Lyophilized. Contains PBS.|
|Other Product Data||
UniProt link O14763: TRAIL-R2 (human) (precursor)
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
PBS containing at least 0.1% BSA should be used for further dilutions.
Stable for at least 6 months after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
TRAIL-R2 (DR5; CD262) is a receptor for the cytotoxic ligand TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-κB.